Literature DB >> 30946430

Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors.

Chunyu Wang1, Andreas Rimner1, Daphna Y Gelblum1, Jessica Flynn2, Andrew Jackson3, Ellen Yorke3, Abraham J Wu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30946430      PMCID： PMC6512294          DOI： 10.1001/jamaoncol.2019.0205

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer.

Authors:  Robert Timmerman; Ronald McGarry; Constantin Yiannoutsos; Lech Papiez; Kathy Tudor; Jill DeLuca; Marvene Ewing; Ramzi Abdulrahman; Colleen DesRosiers; Mark Williams; James Fletcher
Journal:  J Clin Oncol       Date:  2006-10-20       Impact factor: 44.544

2.  Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer.

Authors:  Hilâl Tekatli; Niels Haasbeek; Max Dahele; Patricia De Haan; Wilko Verbakel; Eva Bongers; Sayed Hashemi; Esther Nossent; Femke Spoelstra; Adrianus J de Langen; Ben Slotman; Suresh Senan
Journal:  J Thorac Oncol       Date:  2016-03-21       Impact factor: 15.609

3.  Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree.

Authors:  Justin M Haseltine; Andreas Rimner; Daphna Y Gelblum; Ankit Modh; Kenneth E Rosenzweig; Andrew Jackson; Ellen D Yorke; Abraham J Wu
Journal:  Pract Radiat Oncol       Date:  2015-11-11

4.  Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).

Authors:  Brandon M Barney; Svetomir N Markovic; Nadia N Laack; Robert C Miller; Jann N Sarkaria; O Kenneth Macdonald; Heather J Bauer; Kenneth R Olivier
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-09-01       Impact factor: 7.038

5.  The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors.

Authors:  Joe H Chang; Ian Poon; Darby Erler; Liying Zhang; Patrick Cheung
Journal:  Radiother Oncol       Date:  2018-07-23       Impact factor: 6.280

6.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316
  6 in total
  5 in total

1.  Analysis of pneumonitis and esophageal injury after stereotactic body radiation therapy for ultra-central lung tumors.

Authors:  Chunyu Wang; Andreas Rimner; Daphna Y Gelblum; Rosalind Dick-Godfrey; Dominique McKnight; Danielle Torres; Jessica Flynn; Zhigang Zhang; Baho Sidiqi; Andrew Jackson; Ellen Yorke; Abraham J Wu
Journal:  Lung Cancer       Date:  2020-07-08       Impact factor: 5.705

Review 2.  Safety of stereotactic ablative body radiation for ultracentral stage I non-small cell lung cancer.

Authors:  Abraham Jing-Ching Wu
Journal:  Transl Lung Cancer Res       Date:  2019-09

3.  Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: a single institution real life experience.

Authors:  Elodie Guillaume; Ronan Tanguy; Myriam Ayadi; Line Claude; Sandrine Sotton; Coralie Moncharmont; Nicolas Magné; Isabelle Martel-Lafay
Journal:  Br J Radiol       Date:  2021-11-26       Impact factor: 3.039

4.  Severe Pulmonary Toxicity With Concurrent Anlotinib and Chemoradiotherapy in Stage III NSCLC: The ALTER-L042 Phase 1 Clinical Trial.

Authors:  Hui Zhu; Wenxiao Jia; Xuquan Jing; Wei Huang; Linlin Wang; Jinming Yu
Journal:  JTO Clin Res Rep       Date:  2022-05-13

5.  Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.

Authors:  Cole R Steber; Ryan T Hughes; Michael H Soike; Travis Jacobson; Corbin A Helis; Joshua C Farris; Michael K Farris
Journal:  Clin Lung Cancer       Date:  2020-09-18       Impact factor: 4.785
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.